CORAL GABLES, Fla., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX - News) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will present CPP-115 progress at the 2012 Epilepsy Pipeline Update Conference on Thursday, February 2nd at 11:20 a.m. PST. The conference will be held on February 2nd through February 4th at the Hyatt Regency Hotel in San Francisco, California. Hosted by the Epilepsy Therapy Project, the 2012 Epilepsy Pipeline Update Conference is a showcase of emerging and established central nervous system (CNS) companies presenting their strategies, drug candidates and development programs to potential investors and partners.
CPP-115 is Catalyst's next-generation GABA aminotransferase (GABA-AT) inhibitor that is in Phase I(a) development targeting cocaine dependency, infantile spasms and refractory partial complex seizures, along with other potential CNS indications. Catalyst's presentation materials from the conference will be posted on February 2nd at http://www.catalystpharma.com under "Events & Presentations" in the "Investors" section.
About Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine dependency. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine dependency. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, a next-generation GABA aminotransferase inhibitor, which is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and for other selected CNS indications. CPP-115 has been designated as a "Fast Track" development program for the treatment of cocaine dependency and has been granted orphan drug designation for the treatment of infantile spasms, both by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to http://www.catalystpharma.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-115 will be determined to be safe for use in humans, whether CPP-115 will be effective for the treatment of addiction, infantile spasms or other CNS indications, whether CPP-109 or CPP-115 will ever be approved for commercialization, and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.